Jonas Klingström

Professor Jonas Klingström is affiliated with Linköping University's Department of Biomedical and Clinical Sciences (BKV), within the Faculty of Medicine and Health Sciences. His research focuses on understanding the mechanisms of zoonotic viruses, particularly hantaviruses and coronaviruses, investigating how these pathogens modulate inflammatory responses and cell-cell signaling. Key interests include viral pathogenesis, immune system interactions, and developing treatments for hantavirus-related diseases like hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS).

His work combines clinical samples from patients with in vitro models using primary endothelial and immune cells. Notable contributions include elucidating the role of IL-6 trans-signaling in hantavirus-induced barrier dysfunction and identifying immunological factors linked to disease severity. Research also extends to SARS-CoV-2, examining immune responses in immunocompromised individuals and vaccine efficacy.

Professor Klingström leads the Molecular Medicine and Virology Division (MMV), integrating molecular biology studies with biomedical education programs. His team collaborates on antiviral drug discovery, such as macropinocytosis inhibitors, and improving viral isolation logistics for public health applications. Recent publications span hantavirus classification updates, SARS-CoV-2 immune correlates, and viral protein network analyses.

No scientific awards are explicitly listed in the provided text. His research group actively explores translational approaches to combat viral diseases through a combination of fundamental science and clinical relevance.